Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.56 |
| ▸ | JAK3 | P52333 | 1/20 | 0.56 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.44 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.44 |
| ▸ | TLK2 | Q86UE8 | 1/20 | 0.43 |
| ▸ | BCL6 | P41182 | 1/20 | 0.42 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | KIT | P10721 | 5/20 | 0.42 |
| ▸ | BRAF | P15056 | 5/20 | 0.42 |
| ▸ | FLT1 | P17948 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4034696 | 0.93 | JAK3 (0.47) | IRAK4JAK3P4HTMRXFP1KIT | |
| SCHEMBL6542947 | 0.92 | JAK3 (0.59) | IRAK4JAK3PTK2PTK2BTLK2 | |
| SCHEMBL4036359 | 0.88 | JAK3 (0.54) | IRAK4JAK3PTK2PTK2BTLK2 | |
| SCHEMBL4040683 | 0.88 | JAK3 (0.54) | IRAK4JAK3KITBRAF | |
| SCHEMBL4034865 | 0.87 | IRAK4 (0.53) | IRAK4JAK3PTK2PTK2BTLK2 | |
| SCHEMBL4036464 | 0.86 | JAK3 (0.52) | IRAK4JAK3PTK2PTK2BTLK2 | |
| SCHEMBL6542886 | 0.85 | JAK3 (0.51) | IRAK4JAK3KITBRAFFLT1 | |
| SCHEMBL4041203 | 0.84 | JAK3 (0.55) | IRAK4JAK3PTK2PTK2BTLK2 | |
| SCHEMBL6543366 | 0.81 | KIT (0.64) | IRAK4JAK3KITBRAF | |
| SCHEMBL4034613 | 0.81 | JAK3 (0.52) | IRAK4JAK3KITBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1392680-B1 | SELECTIVE ANTHRANILAMIDE PYRIDINE AMIDES AS INHIBITORS OF VEGFR-2 AND VEGFR-3 | BAYER SCHERING PHARMA AG (DE) | 2009-07-22 | — | — | EP | disclosed |
| US-20040254185-A1 | Selective anthranilamide pyridine amides as inhibitors of vegfr-2 and vegfr-3 | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-12-16 | — | — | US | disclosed |
| EP-1392680-A2 | SELECTIVE ANTHRANILAMIDE PYRIDINE AMIDES AS INHIBITORS OF VEGFR-2 AND VEGFR-3 | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002090352-A2 | SELECTIVE ANTHRANILAMIDE PYRIDINE AMIDES AS INHIBITORS OF VEGFR-2 AND VEGFR-3 | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254185-A1 | Selective anthranilamide pyridine amides as inhibitors of vegfr-2 and vegfr-3 | FLT4, KDR, FLT1 | IRAK4 159/4885JAK3 33/4885PTK2 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.